Back to first-pass browser

First-pass extracted concept

minimal residual disease

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

MRD

Extracted Explainers

What the tool is doing

MRD refers to detection of residual leukemia burden beyond conventional response assessment. In this review, MRD status is used to support a proposed AML response category.

Source 1DOIPubMed

Resources required

Implementation requires assays capable of detecting MRD, but the abstract does not name specific platforms or thresholds.

Source 1DOIPubMed

What problem it solves

It helps refine response assessment by adding residual disease information to AML management recommendations.

Source 1DOIPubMed

What it does not solve

The abstract does not show that MRD alone determines diagnosis, treatment choice, or standardized assay execution.

Source 1DOIPubMed

Alternatives

The abstract contrasts MRD-based response assessment with prior response frameworks that did not explicitly incorporate MRD status.

Source 1DOIPubMed

Evidence Snippets

Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD)... The recommendations include ... a proposal for a response category based on MRD status
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1recommendation updatesupports2016Source 1DOIPubMed

The updated recommendations include criteria for progressive disease in adult AML.

Claim 2recommendation updatesupports2016Source 1DOIPubMed

The updated recommendations propose a response category based on MRD status.

Claim 3review scope summarysupports2016Source 1DOIPubMed

Recent advances in AML genomics, genetic testing assays, MRD detection assays, and novel antileukemic agents motivated updated ELN recommendations for diagnosis and management in adults.